- Home
- CHRS vs MFIN Comparison
CHRS vs MFIN Comparison
Compare CHRS & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MFIN
- Stock Information
- Founded
- CHRS 2010
- MFIN 1995
- Country
- CHRS United States
- MFIN United States
- Employees
- CHRS N/A
- MFIN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MFIN Finance: Consumer Services
- Sector
- CHRS Health Care
- MFIN Finance
- Exchange
- CHRS Nasdaq
- MFIN Nasdaq
- Market Cap
- CHRS 191.3M
- MFIN 190.0M
- IPO Year
- CHRS 2014
- MFIN 1996
- Fundamental
- Price
- CHRS $1.46
- MFIN $9.49
- Analyst Decision
- CHRS Strong Buy
- MFIN
- Analyst Count
- CHRS 4
- MFIN 0
- Target Price
- CHRS $5.38
- MFIN N/A
- AVG Volume (30 Days)
- CHRS 2.3M
- MFIN 50.2K
- Earning Date
- CHRS 11-06-2024
- MFIN 02-18-2025
- Dividend Yield
- CHRS N/A
- MFIN 4.64%
- EPS Growth
- CHRS N/A
- MFIN N/A
- EPS
- CHRS N/A
- MFIN 1.69
- Revenue
- CHRS $304,340,000.00
- MFIN $293,257,000.00
- Revenue This Year
- CHRS $2.47
- MFIN N/A
- Revenue Next Year
- CHRS N/A
- MFIN $10.95
- P/E Ratio
- CHRS N/A
- MFIN $5.61
- Revenue Growth
- CHRS 44.19
- MFIN 18.48
- 52 Week Low
- CHRS $0.66
- MFIN $6.48
- 52 Week High
- CHRS $2.97
- MFIN $10.50
- Technical
- Relative Strength Index (RSI)
- CHRS 50.05
- MFIN 51.10
- Support Level
- CHRS $1.44
- MFIN $8.74
- Resistance Level
- CHRS $1.60
- MFIN $9.56
- Average True Range (ATR)
- CHRS 0.13
- MFIN 0.30
- MACD
- CHRS -0.03
- MFIN -0.02
- Stochastic Oscillator
- CHRS 26.19
- MFIN 76.53
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.